Lilly’s weight loss pill Foundayo now available in U.S.

FDA approved Eli Lilly's oral weight-loss pill Foundayo (orforglipron) on April 1, 2026, with U.S. retail availability and telehealth distribution beginning immediately; self-pay pricing starts at $149/month (lowest dose), insured as low as $25/month, and Medicare Part D beneficiaries eligible for $50/month from July 1. ATTAIN-1 highest-dose on-treatment results showed average loss of 27.3 lbs (12.4%) vs 2.2 lbs (0.9%) for placebo; the registration program enrolled >4,500 patients. Market reaction and analyst moves include a 27% share rise over the past year, market cap ~$853B, shares trading near $953, and multiple firms raising or reiterating price targets (BofA $1,294; Leerink $1,296; Truist $1,281), while Lilly amended an AC Immune deal with a CHF10m upfront payment.

Analysis

Oral small-molecule GLP-1s change the demand curve: they lower initiation friction (no injections, easier dispensing) and therefore expand the addressable population into marginal, more price-sensitive cohorts. That expansion increases script volumes but also invites steeper PBM and retail pricing pressure; manufacturers win on unit economics only if persistence and net pricing hold.

Second-order supply effects favor CMOs and oral-formulation chemistry platforms over injectable supply chains—expect outsized revenues for contract manufacturers that scale tablet capacity quickly, and margin compression for sterile injectable CDMOs. Near-term commercial execution (distribution breadth, telehealth integration, coupon penetration) will determine who captures share in the first 3–12 months; drug safety signals or payor formulary exclusions can flip the adoption curve inside a quarter.

AC Immune’s deal reprioritizes Lilly’s R&D cadence toward small molecules and de-risks a cash runway for ACIU, but the economics are modest versus launch economics and unlikely to move ACIU’s valuation materially without specific milestones. Contrarian risk: the market is pricing a durable, high-margin replacement to existing chronic obesity Rx; if adherence or reimbursement disappoints, the re-rate is vulnerable and short-dated option holders stand to lose most.

Key Decisions for Investors

• Long LLY equity (6–12 months): buy size to represent 2–4% of portfolio. Rationale: upside from faster-than-expected uptake and favorable PBM contracts; risk: formulary resistance or adverse safety headlines. Use a 15% trailing stop or hedge with 6–9 month puts if you want capped downside.
• LLY call-spread (directional, defined-risk): buy Jan-2027 1x call spread (long lower strike, short higher strike) to capture re-rate with limited capital. Reward: asymmetric upside if market rewards uptake; risk: total premium. Size limited to 0.5–1% notional of equity exposure.
• Pair trade (market-neutral, 6–12 months): long LLY / short NVO equal notional. Rationale: play share migration to differentiated oral offering while hedging GLP-1 sector beta. Risk: NVO may defend with rapid pricing/promotions; cap pair size and monitor weekly scripts/market-share datapoints.
• Speculative small-cap: buy ACIU (3–9 months), 0.5–1% position. Rationale: CHF upfront shows partnership traction and de-risks program milestones; risk: payment quantum is small and clinical readouts drive value. Set a 30–40% profit target and 30% stop-loss.